Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today ...
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema (DM ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results